|
|
|
News Releases |
 |
All Releases
 |
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding
Jan 6, 2010
|
16.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Jan. 6, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has rec...
|
|
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Dec 21, 2009
|
20.2 KB |
|
| |
JERUSALEM, Israel, BOTHELL, WA and VANCOUVER, Canada, Dec. 21, 2009 (Canada NewsWire via COMTEX News Network) -- -- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 --
-- Significantly strengthens Teva's oncology offerings with novel therapeut...
|
|
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
Dec 20, 2009
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Dec. 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.
A live webcast will be available through the Investor Relations page of the OncoGenex Web si...
|
|
OncoGenex Reports Third Quarter 2009 Financial Results
Nov 5, 2009
|
21.3 KB |
|
| |
BOTHELL, WA and VANCOUVER Nov. 5, 2009 (Canada NewsWire via COMTEX News Network) -- Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and re...
|
|
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Nov 2, 2009
|
12.7 KB |
|
| |
BOTHELL, WA and VANCOUVER Nov. 2, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon...
|
|
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Oct 9, 2009
|
14.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Oct. 9, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award...
|
|
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
Oct 6, 2009
|
15.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Oct. 6, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with...
|
|
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Sep 3, 2009
|
12.0 KB |
|
| |
BOTHELL, WA and VANCOUVER, Sep. 3, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:
...
|
|
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Aug 13, 2009
|
15.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, Aug. 13, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This tri...
|
|
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Aug 10, 2009
|
14.5 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Aug. 10, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotid...
|
|
OncoGenex Reports Second Quarter 2009 Financial Results
Aug 6, 2009
|
20.5 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Aug. 6, 2009 (Canada NewsWire via COMTEX News Network) --
>
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the second quarter and six months ended ...
|
|
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Aug 3, 2009
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, Aug. 3, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results...
|
|
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Jul 24, 2009
|
14.4 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jul 24, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross pr...
|
|
OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Jul 20, 2009
|
14.0 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jul 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering. The tran...
|
|
OncoGenex Pharmaceuticals Added to Russell Indexes
Jun 30, 2009
|
14.4 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Jun 30, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer, announced today that the Company was added to the Russell 3000(R) I...
|
|
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Jun 26, 2009
|
16.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jun 26, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS prospectus under the multi-jurisdictional disclosure system in the Province of Bri...
|
|
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Jun 24, 2009
|
16.7 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Jun 24, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design of a Phase 3 registration tria...
|
|
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
May 30, 2009
|
22.3 KB |
|
| |
BOTHELL, WA, and VANCOUVER, May 30, 2009 (Canada NewsWire via COMTEX News Network) -- Webcast at 7:10 p.m. Eastern Time Today
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Ana...
|
|
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
May 30, 2009
|
17.8 KB |
|
| |
BOTHELL, WA, and VANCOUVER, May 30, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427...
|
|
OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
May 27, 2009
|
12.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, May 27, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) on Saturd...
|
|
|
= add release to Briefcase
|
|
|
|
0.77
